Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
(2020)
Journal Article
Smith, J. A., Kitt, M. M., Morice, A., Birring, S. S., McGarvey, L. P., Sher, M. R., Li, Y. P., Wu, W. C., Xu, Z. J., Muccino, D. R., Ford, A. P., Hull, J., Carr, W. W., Goldsobel, A. B., Gross, G. N., Holcomb, J. R., Hussain, I., Spangenthal, S., Storms, W., Elkayam, D., …Iyer, V. (2020). Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. The lancet. Respiratory medicine, 8(8), 775-785. https://doi.org/10.1016/S2213-2600%2819%2930471-0
Background: Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatm... Read More about Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.